Katia Cannita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katia Cannita has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Corrado Ficorella
University of L'Aquila, Medical Oncology, L'Aquila, Italy
145 shared publications - Alessio Cortellini
Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
143 shared publications - Daniele Santini
Medical Oncology, University Campus Bio-Medico, 00128 Roma, Italy
142 shared publications - Federica Zoratto
UOC Oncologia, Ospedale Santa Maria Goretti, ASL Latina, 04100 Latina, Italy
142 shared publications - Marco Filetti
Phase 1 Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
142 shared publications - Marco Russano
Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Roma 00128, Italy; Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Roma 00128, Italy
142 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Summary of baseline characteristics of patients included in the targeted transcriptome analysis.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Summary of baseline characteristics of patients included in the targeted transcriptome analysis.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Details of diabetes medications.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Details of diabetes medications.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
A) Heat map of the 770 transcripts analyzed with the Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared with non-diabetic controls (n=11). B) Heat map of selected differently transcripted genes.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
A) Heat map of the 770 transcripts analyzed with the Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared with non-diabetic controls (n=11). B) Heat map of selected differently transcripted genes.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on other oral antidiabetic drugs and insulin therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), patients not receiving other oral diabetes medications and insulin therapy 17.8 months (95%CI: 15.4 – 19.7; 750 events). B) Progression Free Survival whole cohort; other oral diabetes medications and insulin therapy: 8.2 months (95%CI: 6.2-11.4; 106 events), patients not receiving other oral diabetes medications and insulin therapy: 8.1 months (95%CI: 7.1 – 9.2; 951 events).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on other oral antidiabetic drugs and insulin therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), patients not receiving other oral diabetes medications and insulin therapy 17.8 months (95%CI: 15.4 – 19.7; 750 events). B) Progression Free Survival whole cohort; other oral diabetes medications and insulin therapy: 8.2 months (95%CI: 6.2-11.4; 106 events), patients not receiving other oral diabetes medications and insulin therapy: 8.1 months (95%CI: 7.1 – 9.2; 951 events).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), patients not receiving metformin: 19.0 months (95%CI: 16.4 – 21.1; 732 events). B) Progression Free Survival whole cohort; patients on metformin: 7.9 months (95%CI: 5.3-10.1; 124 events), patients not receiving metformin: 8.3 months (95%CI: 7.3 – 9.5; 933 events).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), patients not receiving metformin: 19.0 months (95%CI: 16.4 – 21.1; 732 events). B) Progression Free Survival whole cohort; patients on metformin: 7.9 months (95%CI: 5.3-10.1; 124 events), patients not receiving metformin: 8.3 months (95%CI: 7.3 – 9.5; 933 events).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts identified in diabetic samples (n = 11) versus non-diabetic controls (n = 11). The transcripts achieving the highest statistical significance (p value <0.05) are highlighted by the presence of the corresponding gene name. Significantly downregulated transcripts: HRAS, Ras oncogene family (p=0.009); GTF3C1, transcription factor of the TFIIIC complex (p=0.018); LAG3, key immune checkpoint for T cell modulation (p=0.023); BIRC5, survivin – modulator of programmed cell death (p=0.038); CXCL9 (p=0.038) and CXCL11 (p=0.048), two chemokines mediating inflammatory response; OAS3, interferon-induced enzyme (p=0.04). Significantly upregulated transcripts: IL22RA1, cytokine receptor (p=0.01); MME, transmembrane glycoprotein (p=0.02).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts identified in diabetic samples (n = 11) versus non-diabetic controls (n = 11). The transcripts achieving the highest statistical significance (p value <0.05) are highlighted by the presence of the corresponding gene name. Significantly downregulated transcripts: HRAS, Ras oncogene family (p=0.009); GTF3C1, transcription factor of the TFIIIC complex (p=0.018); LAG3, key immune checkpoint for T cell modulation (p=0.023); BIRC5, survivin – modulator of programmed cell death (p=0.038); CXCL9 (p=0.038) and CXCL11 (p=0.048), two chemokines mediating inflammatory response; OAS3, interferon-induced enzyme (p=0.04). Significantly upregulated transcripts: IL22RA1, cytokine receptor (p=0.01); MME, transmembrane glycoprotein (p=0.02).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Summary of baseline characteristics’ distribution between patients on other oral antidiabetic drugs/insulin only and those who were not on diabetes medications.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Summary of baseline characteristics’ distribution between patients on other oral antidiabetic drugs/insulin only and those who were not on diabetes medications.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Tumour micron-environment transcriptome analysis.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Tumour micron-environment transcriptome analysis.